Nanomaterial-Based Tumor Photothermal Immunotherapy

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670–691. doi:10.1016/j.cell.2016.11.03728187288
   PubMed Web of Science ®Google Scholar
• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904. doi:10.1038/nm146916892035
   PubMed Web of Science ®Google Scholar
• Pavelic SK, Sedic M, Bosnjak H, et al. Metastasis: new perspectives on an old problem. Mol Cancer. 2011;10(1):22. doi:10.1186/1476-4598-10-2221342498
   PubMedGoogle Scholar
• Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2012;12(1):39–50.
   Web of Science ®Google Scholar
• Zhang P, Zhai Y, Cai Y, et al. Nanomedicine-based immunotherapy for the treatment of cancer metastasis. Adv Mater. 2019;31(49):1904156. doi:10.1002/adma.201904156
   PubMed Web of Science ®Google Scholar
• Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293–301.25592534
   PubMed Web of Science ®Google Scholar
• Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851–860. doi:10.1038/nm.412327376576
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Shevach EM, Trinchieri G, et al. Highlights of 10 years of immunology in nature reviews immunology. Nat Rev Immunol. 2011;11(10):693–702.21941295
   PubMed Web of Science ®Google Scholar
• Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004;305(5681):200–205. doi:10.1126/science.110036915247469
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature. 2001;411(6835):380–384. doi:10.1038/3507724611357146
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Cancer immunotherapy. Science. 2013;342(6165):1432–1433. doi:10.1126/science.342.6165.143224357284
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489. doi:10.1038/nature1067322193102
   PubMed Web of Science ®Google Scholar
• Maggon K. Monoclonal antibody “gold rush. Curr Med Chem. 2007;14(18):1978–1987. doi:10.2174/09298670778136850417691940
   PubMed Web of Science ®Google Scholar
• Zhang X, Gordon JR, Xiang J. Advances in dendritic cell-based vaccine of cancer. Cancer Biother Radiopharm. 2002;17(6):601–619. doi:10.1089/10849780232097021712537664
   PubMed Web of Science ®Google Scholar
• Burgdorf SK, Fischer A, Myschetzky PS, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell-based vaccine. Oncol Rep. 2008;20(6):1305–1311.19020707
   PubMed Web of Science ®Google Scholar
• Curran KJ, Brentjens RJ. Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol. 2015;33(15):1703–1706. doi:10.1200/JCO.2014.60.344925897155
   PubMed Web of Science ®Google Scholar
• Yip A, Webster RM. The market for chimeric antigen receptor T cell therapies. Nat Rev Drug Discov. 2018;17(3):161–162. doi:10.1038/nrd.2017.26629375140
   PubMed Web of Science ®Google Scholar
• Yadav DK, de Lu C, Yadav RK. Vaccine therapy for pancreatic cancer: a battle against deadly cancer. Cancer Sci Ther. 2014;6:268–277.
   Google Scholar
• Aurisicchio L, Pallocca M, Ciliberto G, et al. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J Exp Clin Cancer Res. 2018;37(1):86. doi:10.1186/s13046-018-0751-129678194
   PubMedGoogle Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561–584.26228759
   PubMed Web of Science ®Google Scholar
• Yuan J, Gnjatic S, Li H, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008;105(51):20410–20415. doi:10.1073/pnas.081011410519074257
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa100346620525992
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894. doi:10.1200/JCO.2014.56.273625667295
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.000000000000023926558876
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Vanderwalde AM, Rose I, et al. Distribution of PD-L1 expression in diverse cancer types: experience with over 10,000 cases. J Clin Oncol. 2016;34:4. doi:10.1200/JCO.2016.34.15_suppl.11548
   Web of Science ®Google Scholar
• Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, Phase 2 trial. Lancet Oncol. 2016;17(10):1374–1385. doi:10.1016/S1470-2045(16)30364-327592805
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. doi:10.1038/s41467-017-01062-w29070816
   PubMed Web of Science ®Google Scholar
• Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29(1):250–255. doi:10.1093/annonc/mdx64229045547
   PubMed Web of Science ®Google Scholar
• Costa R, Costa RB, Talamantes SM, et al. Analyses of selected safety endpoints in Phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities. Oncotarget. 2017;8(40):67782–67789. doi:10.18632/oncotarget.1884728978071
   PubMedGoogle Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa160921427806233
   PubMed Web of Science ®Google Scholar
• Tang C, Wang X, Soh H, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2(9):831–838. doi:10.1158/2326-6066.CIR-14-006925187273
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–265. doi:10.1093/jnci/djs62923291374
   PubMed Web of Science ®Google Scholar
• Niu LZ, Li JL, Zeng JY, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol. 2013;19(22):3473–3480. doi:10.3748/wjg.v19.i22.347323801841
   PubMed Web of Science ®Google Scholar
• Niu L, Chen J, He L, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas. 2013;42(7):1143–1149. doi:10.1097/MPA.0b013e3182965dde23899940
   PubMed Web of Science ®Google Scholar
• Yuan YY, Niu LZ, Mu F, et al. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer. Cryobiology. 2013;67(2):235–240. doi:10.1016/j.cryobiol.2013.08.00123948179
   PubMed Web of Science ®Google Scholar
• Vankayala R, Hwang KC. Nea-infrared-light-activatable nanomaterial-mediated phototheranostic nanomedicines: an emerging paradigm for cancer treatment. Adv Mater. 2018;30(23):1706320.
   PubMed Web of Science ®Google Scholar
• Xu L, Mou F, Gong H, et al. Light-driven micro/nanomotors: from fundamentals to applications. Chem Soc Rev. 2017;46(22):6905–6926.28949354
   PubMed Web of Science ®Google Scholar
• Luo L, Bian Y, Liu Y, et al. Combined near infrared photothermal therapy and chemotherapy using gold nanoshells coated liposomes to enhance antitumor effect. Small. 2016;12(30):4103–4112. doi:10.1002/smll.20150396127294601
   PubMed Web of Science ®Google Scholar
• Song J, Yang X, Yang Z, et al. Rational design of branched nanoporous gold nanoshells with enhanced physico-optical properties for optical imaging and cancer therapy. ACS Nano. 2017;11(6):6102–6113. doi:10.1021/acsnano.7b0204828605594
   PubMed Web of Science ®Google Scholar
• Manivasagan P, Jun SW, Hoang G, et al. Anti-EGFR antibody conjugated thiol chitosan-layered gold nanoshells for dual-modal imaging-guided cancer combination therapy. J Control Release. 2019;311:26–42. doi:10.1016/j.jconrel.2019.08.00731401198
   PubMed Web of Science ®Google Scholar
• Lee C, Hwang HS, Lee S, et al. Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. Adv Mater. 2017;29(13):1605563. doi:10.1002/adma.201605563
   Web of Science ®Google Scholar
• Li Z, Huang H, Tang S, et al. Small gold nanorods laden macrophages for enhanced tumor coverage in photothermal therapy. Biomaterials. 2016;74:144–154. doi:10.1016/j.biomaterials.2015.09.03826454052
   PubMed Web of Science ®Google Scholar
• An L, Wang Y, Lin J, et al. Macrophages-mediated delivery of small gold nanorods for tumor hypoxia photoacoustic imaging and enhanced photothermal therapy. ACS Appl Mater Interfaces. 2019;11(17):15251–15261. doi:10.1021/acsami.9b0049530964253
   PubMed Web of Science ®Google Scholar
• Feng Y, Cheng Y, Chang Y, et al. Time-staggered delivery of erlotinib and doxorubicin by gold nanocages with two smart polymers for reprogrammable release and synergistic with photothermal therapy. Biomaterials. 2019;217:119327.31299626
   PubMed Web of Science ®Google Scholar
• Wu S, Li A, Zhao X, et al. Silica-coated gold–silver nanocages as photothermal antibacterial agents for combined anti-infective therapy. ACS Appl Mater Interfaces. 2019;11(19):17177–17183. doi:10.1021/acsami.9b0114930997794
   PubMed Web of Science ®Google Scholar
• Zhan C, Huang Y, Lin G, et al. A gold nanocage/cluster hybrid structure for whole-body multispectral optoacoustic tomography imaging, EGFR inhibitor delivery, and photothermal therapy. Small. 2019;15(33):1900309. doi:10.1002/smll.201900309
   Web of Science ®Google Scholar
• Xu P, Ning P, Wang JJ, et al. Precise control of apoptosis via gold nanostars for dose dependent photothermal therapy of melanoma. J Mater Chem B. 2019;7(44):6934–6944. doi:10.1039/C9TB01956A31675048
   PubMed Web of Science ®Google Scholar
• Chen CC, Chang DY, Li JJ, et al. Investigation of biodistribution and tissue penetration of PEGylated gold nanostars and their application for photothermal cancer treatment in tumor-bearing mice. J Mater Chem B. 2020;8(1):65–77. doi:10.1039/C9TB02194A31768514
   PubMed Web of Science ®Google Scholar
• Xu P, Feng QS, Yang XR, et al. Near infrared light triggered cucurbit [7] uril-stabilized gold nanostars as a supramolecular nanoplatform for combination treatment of cancer. Bioconjug Chem. 2018;29(8):2855–2866. doi:10.1021/acs.bioconjchem.8b0043830025449
   PubMed Web of Science ®Google Scholar
• Yang J, Su H, Sun W, et al. Dual chemodrug-loaded single-walled carbon nanohorns for multimodal imaging-guided chemo-photothermal therapy of tumors and lung metastases. Theranostics. 2018;8(7):1966–1984. doi:10.7150/thno.2384829556368
   PubMed Web of Science ®Google Scholar
• Lu GH, Shang WT, Deng H, et al. Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging. Biomaterials. 2019;195:13–22. doi:10.1016/j.biomaterials.2018.12.02530599289
   PubMed Web of Science ®Google Scholar
• Suo X, Eldridge BN, Zhang H, et al. P-glycoprotein-targeted photothermal therapy of drug-resistant cancer cells using antibody-conjugated carbon nanotubes. ACS Appl Mater Interfaces. 2018;10(39):33464–33473. doi:10.1021/acsami.8b1197430188117
   PubMed Web of Science ®Google Scholar
• Wang H, Mu Q, Wang K, et al. Nitrogen and boron dual-doped graphene quantum dots for near-infrared second window imaging and photothermal therapy. Appl Mater Today. 2019;14:108–117. doi:10.1016/j.apmt.2018.11.01131538108
   PubMed Web of Science ®Google Scholar
• Gu Z, Zhu S, Yan L, et al. Graphene-based smart platforms for combined cancer therapy. Adv Mater. 2019;31(9):1800662.
   PubMed Web of Science ®Google Scholar
• Jiang W, Mo F, Lin Y, et al. Tumor targeting dual stimuli responsive controllable release nanoplatform based on DNA-conjugated reduced graphene oxide for chemo-photothermal synergetic cancer therapy. J Mater Chem B. 2018;6(26):4360–4367. doi:10.1039/C8TB00670A32254511
   PubMed Web of Science ®Google Scholar
• Li N, Sun Q, Yu Z, et al. Nuclear-targeted photothermal therapy prevents cancer recurrence with near-infrared triggered copper sulfide nanoparticles. ACS Nano. 2018;12(6):5197–5206. doi:10.1021/acsnano.7b0687029894162
   PubMed Web of Science ®Google Scholar
• Wang D, Dong H, Li M, et al. Erythrocyte–cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal/chemotherapy of melanoma. ACS Nano. 2018;12(6):5241–5252. doi:10.1021/acsnano.7b0835529800517
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhao J, Qiao Y, et al. Simultaneous multimodal imaging and photothermal therapy via renal-clearable manganese-doped copper sulfide nanodots. Appl Mater Today. 2018;13:285–297. doi:10.1016/j.apmt.2018.09.011
   Web of Science ®Google Scholar
• Maji SK, Yu S, Chung K, et al. Synergistic nanozymetic activity of hybrid gold bipyramid-molybdenum disulfide core@ shell nanostructures for two-photon imaging and anticancer therapy. ACS Appl Mater Interfaces. 2018;10(49):42068–42076. doi:10.1021/acsami.8b1544330462488
   PubMed Web of Science ®Google Scholar
• Yu Y, Chi B, Lin L, et al. Microwave-assisted preparation of paramagnetic zwitterionic amphiphilic copolymer hybrid molybdenum disulfide for T 1-weighted magnetic resonance imaging-guided photothermal therapy. J Mater Chem B. 2018;6(40):6391–6398. doi:10.1039/C8TB01660G32254647
   PubMed Web of Science ®Google Scholar
• Shin MH, Park EY, Han S, et al. Multimodal cancer theranosis using hyaluronate-conjugated molybdenum disulfide. Adv Healthc Mater. 2019;8(1):1801036. doi:10.1002/adhm.201801036
   PubMed Web of Science ®Google Scholar
• Pan H, Zhang C, Wang T, et al. In situ fabrication of intelligent photothermal indocyanine green-alginate hydrogel for localized tumor ablation. ACS Appl Mater Interfaces. 2018;11(3):2782–2789. doi:10.1021/acsami.8b16517
   Web of Science ®Google Scholar
• Shan W, Chen R, Zhang Q, et al. Improved stable indocyanine green (ICG)-mediated cancer optotheranostics with naturalized hepatitis B core particles. Adv Mater. 2018;30(28):1707567. doi:10.1002/adma.201707567
   Web of Science ®Google Scholar
• He Q, He X, Deng B, et al. Sorafenib and indocyanine green co-loaded in photothermally sensitive liposomes for diagnosis and treatment of advanced hepatocellular carcinoma. J Mater Chem B. 2018;6(36):5823–5834. doi:10.1039/C8TB01641K32254989
   PubMed Web of Science ®Google Scholar
• Chen WR, Adams RL, Heaton S, et al. Chromophore-enhanced laser-tumor tissue photothermal interaction using an 808-nm diode laser. Cancer Lett. 1995;88(1):15–19. doi:10.1016/0304-3835(94)03609-M7850768
   PubMed Web of Science ®Google Scholar
• Chen WR, Adams RL, Bartels KE, et al. Chromophore-enhanced in vivo tumor cell destruction using an 808-nm diode laser. Cancer Lett. 1995;94(2):125–131. doi:10.1016/0304-3835(95)03837-M7634239
   PubMed Web of Science ®Google Scholar
• Chen WR, Adams RL, Higgins AK, et al. Photothermal effects on murine mammary tumors using indocyanine green and an 808-nm diode laser: an in vivo efficacy study. Cancer Lett. 1996;98(2):169–173. doi:10.1016/S0304-3835(06)80028-58556705
   PubMed Web of Science ®Google Scholar
• Song J, Zhang N, Zhang L, et al. IR780-loaded folate-targeted nanoparticles for near-infrared fluorescence image-guided surgery and photothermal therapy in ovarian cancer. Int J Nanomedicine. 2019;14:2757–2772. doi:10.2147/IJN.S20310831118609
   PubMed Web of Science ®Google Scholar
• Shen Y, Lv W, Yang H, et al. FA-NBs-IR780: novel multifunctional nanobubbles as molecule-targeted ultrasound contrast agents for accurate diagnosis and photothermal therapy of cancer. Cancer Lett. 2019;455:14–25. doi:10.1016/j.canlet.2019.04.02331018151
   PubMed Web of Science ®Google Scholar
• Chen Y, Li Z, Wang H, et al. IR-780 loaded phospholipid mimicking homopolymeric micelles for near-IR imaging and photothermal therapy of pancreatic cancer. ACS Appl Mater Interfaces. 2016;8(11):6852–6858. doi:10.1021/acsami.6b0025126918365
   PubMed Web of Science ®Google Scholar
• Li WT, Peng JR, Tan LW, et al. Mild photothermal therapy/photodynamic therapy/chemotherapy of breast cancer by Lyp-1 modified Docetaxel/IR820 Co-loaded micelles. Biomaterials. 2016;106:119–133. doi:10.1016/j.biomaterials.2016.08.01627561883
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Q, Liu R, et al. A Versatile prodrug strategy to in situ encapsulate drugs in MOF nanocarriers: a case of cytarabine-IR820 prodrug encapsulated ZIF-8 toward chemo-photothermal therapy. Adv Funct Mater. 2018;28(35):1802830. doi:10.1002/adfm.201802830
   Web of Science ®Google Scholar
• Zhang D, Zhang J, Li Q, et al. pH- and enzyme-sensitive IR820-paclitaxel conjugate self-assembled nanovehicles for near-infrared fluorescence imaging-guided chemo-photothermal therapy. ACS Appl Mater Interfaces. 2018;10(36):30092–30102. doi:10.1021/acsami.8b0909830118198
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Senovilla L, et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16(12):3100–3104. doi:10.1158/1078-0432.CCR-09-289120421432
   PubMed Web of Science ®Google Scholar
• Dudek AM, Garg AD, Krysko DV, et al. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev. 2013;24(4):319–333. doi:10.1016/j.cytogfr.2013.01.00523391812
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875.23151605
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.23157435
   PubMed Web of Science ®Google Scholar
• Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014;21(1):39–49. doi:10.1038/cdd.2013.8423832118
   PubMed Web of Science ®Google Scholar
• Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine. 2017;97:123–132. doi:10.1016/j.cyto.2017.05.02428648866
   PubMed Web of Science ®Google Scholar
• Ma Y, Pitt JM, Li Q, et al. The renaissance of anti-neoplastic immunity from tumor cell demise. Immunol Rev. 2017;280(1):194–206.29027231
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33–56. doi:10.1016/S1040-8428(01)00179-212098606
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487–497. doi:10.1016/S1470-2045(02)00818-512147435
   PubMed Web of Science ®Google Scholar
• Burlaka A, Lukin S, Prylutska S, et al. Hyperthermic effect of multi-walled carbon nanotubes stimulated with near infrared irradiation for anticancer therapy: in vitro studies. Exp Oncol. 2010;32(1):48–50.20332757
   PubMedGoogle Scholar
• Habash RWY, Bansal R, Krewski D, et al. Thermal therapy, part 2: hyperthermia techniques. Crit Rev Biomed Eng. 2006;34(6):491–542. doi:10.1615/CritRevBiomedEng.v34.i6.3017725480
   PubMedGoogle Scholar
• Oleson JR, Samulski TV, Leopold KA, et al. Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment. Int J Radiat Oncol Biol Phys. 1993;25(2):289–297. doi:10.1016/0360-3016(93)90351-U8420877
   PubMed Web of Science ®Google Scholar
• Jaque D, Martínez Maestro L, Del Rosal B, et al. Nanoparticles for photothermal therapies. Nanoscale. 2014;6(16):9494–9530.25030381
   PubMed Web of Science ®Google Scholar
• Riley RS, Day ES. Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(4):1449
   Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):271–284. doi:10.1016/S0168-3659(99)00248-510699287
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151. doi:10.1016/j.addr.2010.04.00920441782
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71–79. doi:10.1016/j.addr.2012.10.00223088862
   PubMed Web of Science ®Google Scholar
• Gai S, Yang G, Yang P, et al. Recent advances in functional nanomaterials for light-triggered cancer therapy. Nano Today. 2018;19:146–187. doi:10.1016/j.nantod.2018.02.010
   Web of Science ®Google Scholar
• Zhao J, Zhong D, Zhou S. NIR-I-to-NIR-II fluorescent nanomaterials for biomedical imaging and cancer therapy. J Mater Chem B. 2018;6(3):349–365.32254515
   PubMed Web of Science ®Google Scholar
• Liu B, Li C, Cheng Z, et al. Functional nanomaterials for near-infrared-triggered cancer therapy. Biomater Sci. 2016;4(6):890–909.26971704
   PubMed Web of Science ®Google Scholar
• Zhang P, Hu C, Ran W, et al. Recent progress in light-triggered nanotheranostics for cancer treatment. Theranostics. 2016;6(7):948–968. doi:10.7150/thno.1521727217830
   PubMed Web of Science ®Google Scholar
• Kang H, Mintri S, Menon AV, et al. Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles. Nanoscale. 2015;7(45):18848–18862.26528835
   PubMed Web of Science ®Google Scholar
• Kim H, Beack S, Han S, et al. Multifunctional photonic nanomaterials for diagnostic, therapeutic, and theranostic applications. Adv Mater. 2018;30(10):1701460
   Web of Science ®Google Scholar
• Krishna V, Singh A, Sharma P, et al. Polyhydroxy fullerenes for non-invasive cancer imaging and therapy. Small. 2010;6(20):2236–2241.20818623
   PubMed Web of Science ®Google Scholar
• Shi J, Wang L, Gao J, et al. A fullerene-based multi-functional nanoplatform for cancer theranostic applications. Biomaterials. 2014;35(22):5771–5784. doi:10.1016/j.biomaterials.2014.03.07124746227
   PubMed Web of Science ®Google Scholar
• Shen Y, Skirtach AG, Seki T, et al. Assembly of fullerene-carbon nanotubes: temperature indicator for photothermal conversion. J Am Chem Soc. 2010;132(25):8566–8568. doi:10.1021/ja102602420527750
   PubMed Web of Science ®Google Scholar
• Cheng L, Liu J, Gu X, et al. PEGylated WS2 nanosheets as a multifunctional theranostic agent for in vivo dual-modal CT/photoacoustic imaging guided photothermal therapy. Adv Mater. 2014;26(12):1886–1893. doi:10.1002/adma.20130449724375758
   PubMed Web of Science ®Google Scholar
• Zhang C, Yong Y, Song L, et al. Multifunctional WS2@ poly (ethylene imine) nanoplatforms for imaging guided gene-photothermal synergistic therapy of cancer. Adv Healthc Mater. 2016;5(21):2776–2787. doi:10.1002/adhm.20160063327717238
   PubMed Web of Science ®Google Scholar
• Xie H, Li Z, Sun Z, et al. Metabolizable ultrathin Bi2Se3 nanosheets in imaging-guided photothermal therapy. Small. 2016;12(30):4136–4145.27329254
   PubMed Web of Science ®Google Scholar
• Zhang XD, Chen J, Min Y, et al. Metabolizable Bi2Se3 nanoplates: biodistribution, toxicity, and uses for cancer radiation therapy and imaging. Adv Funct Mater. 2014;24(12):1718–1729. doi:10.1002/adfm.201302312
   Web of Science ®Google Scholar
• Stern JM, Kibanov Solomonov VV, Sazykina E, et al. Initial evaluation of the safety of nanoshell-directed photothermal therapy in the treatment of prostate disease. Int J Toxicol. 2016;35(1):38–46. doi:10.1177/109158181560017026296672
   PubMed Web of Science ®Google Scholar
• Ali MRK, Wu Y, El-Sayed MA. Gold-nanoparticle-assisted plasmonic photothermal therapy advances toward clinical application. J Phys Chem C. 2019;123(25):15375–15393. doi:10.1021/acs.jpcc.9b01961
   Web of Science ®Google Scholar
• Ayala-Orozco C, Urban C, Knight MW, et al. Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells. ACS Nano. 2014;8(6):6372–6381. doi:10.1021/nn501871d24889266
   PubMed Web of Science ®Google Scholar
• Movahedi MM, Alamzadeh Z, Hosseini-Nami S, et al. Investigating the mechanisms behind extensive death in human cancer cells following nanoparticle assisted photo-thermo-radiotherapy. Photodiagnosis Photodyn Ther. 2020;29:101600. doi:10.1016/j.pdpdt.2019.10160031731067
   PubMed Web of Science ®Google Scholar
• Zeinizade E, Tabei M, Shakeri-Zadeh A, et al. Selective apoptosis induction in cancer cells using folate-conjugated gold nanoparticles and controlling the laser irradiation conditions. Artif Cells Nanomed Biotechnol. 2018;46:1026–1038. doi:10.1080/21691401.2018.144311629486617
   PubMed Web of Science ®Google Scholar
• Alamzadeh Z, Beik J, Pirhajati Mahabadi V, et al. Ultrastructural and optical characteristics of cancer cells treated by a nanotechnology based chemo-photothermal therapy method. J Photochem Photobiol B. 2019;192:19–25. doi:10.1016/j.jphotobiol.2019.01.00530665146
   PubMed Web of Science ®Google Scholar
• Mirrahimi M, Abed Z, Beik J, et al. A thermo-responsive alginate nanogel platform co-loaded with gold nanoparticles and cisplatin for combined cancer chemo-photothermal therapy. Pharmacol Res. 2019;143:178–185. doi:10.1016/j.phrs.2019.01.00530611856
   PubMed Web of Science ®Google Scholar
• Huang X, Kang B, Qian W, et al. Comparative study of photothermolysis of cancer cells with nuclear-targeted or cytoplasm-targeted gold nanospheres: continuous wave or pulsed lasers. J Biomed Opt. 2010;15(5):058002. doi:10.1117/1.348653821054128
   PubMed Web of Science ®Google Scholar
• Tong L, Zhao Y, Huff TB, et al. Gold nanorods mediate tumor cell death by compromising membrane integrity. Adv Mater. 2007;19(20):3136–3141. doi:10.1002/adma.20070197419020672
   PubMed Web of Science ®Google Scholar
• Ali MRK, Ibrahim IM, Ali HR, et al. Treatment of natural mammary gland tumors in canines and felines using gold nanorods-assisted plasmonic photothermal therapy to induce tumor apoptosis. Int J Nanomedicine. 2016;11:4849–4863. doi:10.2147/IJN.S10947027703351
   PubMed Web of Science ®Google Scholar
• Li JL, Gu M. Surface plasmonic gold nanorods for enhanced two-photon microscopic imaging and apoptosis induction of cancer cells. Biomaterials. 2010;31(36):9492–9498. doi:10.1016/j.biomaterials.2010.08.06820932571
   PubMed Web of Science ®Google Scholar
• Pérez-Hernández M, Del Pino P, Mitchell SG, et al. Dissecting the molecular mechanism of apoptosis during photothermal therapy using gold nanoprisms. ACS Nano. 2015;9(1):52–61. doi:10.1021/nn505468v25493329
   PubMed Web of Science ®Google Scholar
• Mocan T, Matea CT, Cojocaru I, et al. Photothermal treatment of human pancreatic cancer using PEGylated multi-walled carbon nanotubes induces apoptosis by triggering mitochondrial membrane depolarization mechanism. J Cancer. 2014;5(8):679–688. doi:10.7150/jca.948125258649
   PubMed Web of Science ®Google Scholar
• Ali MRK, Wu Y, Han T, et al. Simultaneous time-dependent surface-enhanced Raman spectroscopy, metabolomics, and proteomics reveal cancer cell death mechanisms associated with gold nanorod photothermal therapy. J Am Chem Soc. 2016;138(47):15434–15442. doi:10.1021/jacs.6b0878727809520
   PubMed Web of Science ®Google Scholar
• Ali MRK, Rahman MA, Wu Y, et al. Efficacy, long-term toxicity, and mechanistic studies of gold nanorods photothermal therapy of cancer in xenograft mice. Proc Natl Acad Sci U S A. 2017;114(15):3110–3118. doi:10.1073/pnas.1619302114
   PubMed Web of Science ®Google Scholar
• Katschinski DM. On heat and cells and proteins. Physiology. 2004;19(1):11–15. doi:10.1152/nips.01403.2002
   Google Scholar
• Fisher JW, Sarkar S, Buchanan CF, et al. Photothermal response of human and murine cancer cells to multiwalled carbon nanotubes after laser irradiation. Cancer Res. 2010;70(23):9855–9864. doi:10.1158/0008-5472.CAN-10-025021098701
   PubMed Web of Science ®Google Scholar
• van den Tempel N, Horsman MR, Kanaar R. Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. Int J Hyperthermia. 2016;32(4):446–454. doi:10.3109/02656736.2016.115721627086587
   PubMed Web of Science ®Google Scholar
• Jego G, Hazoumé A, Seigneuric R, et al. Targeting heat shock proteins in cancer. Cancer Lett. 2013;332(2):275–285. doi:10.1016/j.canlet.2010.10.01421078542
   PubMed Web of Science ®Google Scholar
• Calderwood SK, Khaleque MA, Sawyer DB, et al. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31(3):164–172. doi:10.1016/j.tibs.2006.01.00616483782
   PubMed Web of Science ®Google Scholar
• Wang S, Tian Y, Tian W, et al. Selectively sensitizing malignant cells to photothermal therapy using a CD44-targeting heat shock protein 72 depletion nanosystem. ACS Nano. 2016;10(9):8578–8590. doi:10.1021/acsnano.6b0387427576159
   PubMed Web of Science ®Google Scholar
• Wang L, Gao C, Liu K, et al. Cypate-conjugated porous upconversion nanocomposites for programmed delivery of heat shock protein 70 small interfering RNA for gene silencing and photothermal ablation. Adv Funct Mater. 2016;26(20):3480–3489. doi:10.1002/adfm.201600035
   Web of Science ®Google Scholar
• Wang BK, Yu XF, Wang JH, et al. Gold-nanorods-siRNA nanoplex for improved photothermal therapy by gene silencing. Biomaterials. 2016;78:27–39. doi:10.1016/j.biomaterials.2015.11.02526646625
   PubMed Web of Science ®Google Scholar
• Ali MRK, Ali HR, Rankin CR, et al. Targeting heat shock protein 70 using gold nanorods enhances cancer cell apoptosis in low dose plasmonic photothermal therapy. Biomaterials. 2016;102:1–8. doi:10.1016/j.biomaterials.2016.06.01727318931
   PubMed Web of Science ®Google Scholar
• Wang Z, Li S, Zhang M, et al. Laser-triggered small interfering RNA releasing gold nanoshells against heat shock protein for sensitized photothermal therapy. Adv Sci. 2017;4(2):1600327. doi:10.1002/advs.201600327
   Web of Science ®Google Scholar
• Chen WH, Luo GF, Lei Q, et al. Overcoming the heat endurance of tumor cells by interfering with the anaerobic glycolysis metabolism for improved photothermal therapy. ACS Nano. 2017;11(2):1419–1431. doi:10.1021/acsnano.6b0665828107631
   PubMed Web of Science ®Google Scholar
• Ariyasu S, Mu J, Zhang X, et al. Investigation of thermally induced cellular ablation and heat response triggered by planar MoS2-based nanocomposite. Bioconjug Chem. 2017;28(4):1059–1067. doi:10.1021/acs.bioconjchem.6b0074128228012
   PubMed Web of Science ®Google Scholar
• Liu Y, Shu G, Li X, et al. Human HSP70 promoter-based prussian blue nanotheranostics for thermo-controlled gene therapy and synergistic photothermal ablation. Adv Funct Mater. 2018;28(32):1802026. doi:10.1002/adfm.201802026
   Web of Science ®Google Scholar
• Jiang A, Liu Y, Ma L, et al. Biocompatible heat-shock protein inhibitor-delivered flowerlike short-wave infrared nanoprobe for mild temperature-driven highly efficient tumor ablation. ACS Appl Mater Interfaces. 2019;11((7):):6820–6828. doi:10.1021/acsami.8b2148330677285
   PubMed Web of Science ®Google Scholar
• Wang S, Li L, Ning X, et al. pH-activated heat shock protein inhibition and radical generation enhanced NIR luminescence imaging-guided photothermal tumour ablation. Int J Pharm. 2019;566:40–45. doi:10.1016/j.ijpharm.2019.05.05631129340
   PubMedGoogle Scholar
• Liu Y, Xu M, Zhao Y, et al. Flower-like gold nanoparticles for enhanced photothermal anticancer therapy by the delivery of pooled siRNA to inhibit heat shock stress response. J Mater Chem B. 2019;7(4):586–597. doi:10.1039/C8TB02418A32254792
   PubMed Web of Science ®Google Scholar
• Tian H, Zhang J, Zhang H, et al. Low side-effect and heat-shock protein-inhibited chemo-phototherapy nanoplatform via co-assembling strategy of biotin-tailored IR780 and quercetin. Chem Eng J. 2020;382:123043. doi:10.1016/j.cej.2019.123043
   Web of Science ®Google Scholar
• Huang XF, Ren W, Rollins L, et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res. 2003;63(21):7321–7329.14612530
   PubMed Web of Science ®Google Scholar
• Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem. 2007;101(4):937–949. doi:10.1002/jcb.2118717171643
   PubMed Web of Science ®Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumor micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–354. doi:10.1038/nature1262624048067
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.24202395
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–5912. doi:10.1038/onc.2008.27118836471
   PubMed Web of Science ®Google Scholar
• Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63(4):571–582. doi:10.1007/s00280-008-0881-919083000
   PubMed Web of Science ®Google Scholar
• Song G, Liang C, Gong H, et al. Core–shell MnSe@ Bi2Se3 fabricated via a cation exchange method as novel nanotheranostics for multimodal imaging and synergistic thermoradiotherapy. Adv Mater. 2015;27(40):6110–6117. doi:10.1002/adma.20150300626331476
   PubMed Web of Science ®Google Scholar
• Shen S, Chao Y, Dong Z, et al. Bottom-up preparation of uniform ultrathin rhenium disulfide nanosheets for image-guided photothermal radiotherapy. Adv Funct Mater. 2017;27(28):1700250. doi:10.1002/adfm.201700250
   Web of Science ®Google Scholar
• Cheng L, Shen S, Shi S, et al. FeSe2-decorated Bi2Se3 nanosheets fabricated via cation exchange for chelator-free 64Cu-labeling and multimodal image-guided photothermal-radiation therapy. Adv Funct Mater. 2016;26(13):2185–2197. doi:10.1002/adfm.20150481027110230
   PubMed Web of Science ®Google Scholar
• Wang S, Li X, Chen Y, et al. A facile one-pot synthesis of a two-dimensional MoS2/Bi2S3 composite theranostic nanosystem for multi-modality tumor imaging and therapy. Adv Mater. 2015;27(17):2775–2782. doi:10.1002/adma.20150087025821185
   PubMed Web of Science ®Google Scholar
• Zhao P, Zheng M, Yue C, et al. Improving drug accumulation and photothermal efficacy in tumor depending on size of ICG loaded lipid-polymer nanoparticles. Biomaterials. 2014;35(23):6037–6046. doi:10.1016/j.biomaterials.2014.04.01924776486
   PubMed Web of Science ®Google Scholar
• Zhao R, Han X, Li Y, et al. Photothermal effect enhanced cascade-targeting strategy for improved pancreatic cancer therapy by gold nanoshell@ mesoporous silica nanorod. ACS Nano. 2017;11(8):8103–8113. doi:10.1021/acsnano.7b0291828738680
   PubMed Web of Science ®Google Scholar
• Saha S, Xiong X, Chakraborty PK, et al. Gold nanoparticle reprograms pancreatic tumor microenvironment and inhibits tumor growth. ACS Nano. 2016;10(12):10636–10651. doi:10.1021/acsnano.6b0223127758098
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.01223890059
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature2134928102259
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61. doi:10.1038/nm152317187072
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008;15(9):1499–1509. doi:10.1038/cdd.2008.6718464797
   PubMed Web of Science ®Google Scholar
• Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31(5):1062–1079. doi:10.1038/emboj.2011.49722252128
   PubMed Web of Science ®Google Scholar
• Martins I, Wang Y, Michaud M, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014;21(1):79–91. doi:10.1038/cdd.2013.7523852373
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220(1):47–59. doi:10.1111/j.1600-065X.2007.00573.x17979839
   PubMedGoogle Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195. doi:10.1038/nature0085812110890
   PubMed Web of Science ®Google Scholar
• Binder RJ. Functions of heat shock proteins in pathways of the innate and adaptive immune system. J Immunol. 2014;193(12):5765–5771. doi:10.4049/jimmunol.140141725480955
   PubMed Web of Science ®Google Scholar
• Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15(1):3–12. doi:10.1038/sj.cdd.440226918007663
   PubMed Web of Science ®Google Scholar
• Obeid M, Panaretakis T, Joza N, et al. Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14(10):1848–1850. doi:10.1038/sj.cdd.440220117657249
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059. doi:10.1038/nm162217704786
   PubMed Web of Science ®Google Scholar
• Duan X, Chan C, Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed Engl. 2019;58(3):670–680. doi:10.1002/anie.20180488230016571
   PubMed Web of Science ®Google Scholar
• Sweeney EE, Cano-Mejia J, Fernandes R. Photothermal therapy generates a thermal window of immunogenic cell death in neuroblastoma. Small. 2018;14(20):1800678. doi:10.1002/smll.201800678
   PubMed Web of Science ®Google Scholar
• Hou X, Tao Y, Pang Y, Li X, Jiang G, Liu Y. Nanoparticle-based photothermal and photodynamic immunotherapy for tumor treatment. Int J Cancer. 2018;143(12):3050–3060.29981170
   PubMed Web of Science ®Google Scholar
• Zhou B, Song J, Wang M, et al. BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy. Nanoscale. 2018;10(46):21640–21647. doi:10.1039/C8NR05323E30232481
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao T, Han F, et al. Photothermal and gene therapy combined with immunotherapy to gastric cancer by the gold nanoshell-based system. J Nanobiotechnology. 2019;17(1):80. doi:10.1186/s12951-019-0515-x31277667
   PubMedGoogle Scholar
• Yata T, Takahashi Y, Tan M, et al. DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy. Biomaterials. 2017;146:136–145. doi:10.1016/j.biomaterials.2017.09.01428918263
   PubMed Web of Science ®Google Scholar
• Zhou F, Wu S, Song S, et al. Antitumor immunologically modified carbon nanotubes for photothermal therapy. Biomaterials. 2012;33(11):3235–3242. doi:10.1016/j.biomaterials.2011.12.02922296829
   PubMed Web of Science ®Google Scholar
• Tao Y, Ju E, Ren J, et al. Immunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy. Biomaterials. 2014;35(37):9963–9971. doi:10.1016/j.biomaterials.2014.08.03625224368
   PubMed Web of Science ®Google Scholar
• Guo L, Yan DD, Yang D, et al. Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. ACS Nano. 2014;8(6):5670–5681. doi:10.1021/nn500211224801008
   PubMed Web of Science ®Google Scholar
• Jang B, Xu L, Moorthy MS, et al. Lipopolysaccharide-coated CuS nanoparticles promoted anti-cancer and anti-metastatic effect by immuno-photothermal therapy. Oncotarget. 2017;8(62):105584–105595. doi:10.18632/oncotarget.2233129285274
   PubMedGoogle Scholar
• Chen WR, Adams RL, Carubelli R, Nordquist RE. Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment. Cancer Lett. 1997;115(1):25–30. doi:10.1016/S0304-3835(97)04707-19097975
   PubMed Web of Science ®Google Scholar
• Li L, Yang S, Song L, et al. An endogenous vaccine based on fluorophores and multivalent immunoadjuvants regulates tumor micro-environment for synergistic photothermal and immunotherapy. Theranostics. 2018;8(3):860–873. doi:10.7150/thno.1982629344312
   PubMed Web of Science ®Google Scholar
• Dong X, Liang J, Yang A, et al. Fluorescence imaging guided CpG nanoparticles-loaded IR820-hydrogel for synergistic photothermal immunotherapy. Biomaterials. 2019;209:111–125. doi:10.1016/j.biomaterials.2019.04.02431034980
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32–42. doi:10.1158/2326-6066.CIR-13-001324777248
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206–213. doi:10.1016/j.coi.2006.01.01116464564
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi:10.3389/fphar.2017.0056128878676
   PubMed Web of Science ®Google Scholar
• Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26. doi:10.1186/s12929-017-0329-928376884
   PubMed Web of Science ®Google Scholar
• Wang C, Xu L, Liang C, et al. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater. 2014;26(48):8154–8162. doi:10.1002/adma.20140299625331930
   PubMed Web of Science ®Google Scholar
• Cano-Mejia J, Burga RA, Sweeney EE, et al. Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. Nanomedicine. 2017;13(2):771–781. doi:10.1016/j.nano.2016.10.01527826115
   PubMed Web of Science ®Google Scholar
• Liu Y, Maccarini P, Palmer GM, et al. Synergistic immuno photothermal nanotherapy (SYMPHONY) for the treatment of unresectable and metastatic cancers. Sci Rep. 2017;7(1):8606. doi:10.1038/s41598-017-09116-128819209
   PubMedGoogle Scholar
• Peng J, Yang Q, Xiao Y, et al. Tumor microenvironment responsive drug-dye-peptide nanoassembly for enhanced tumor-targeting, penetration, and photo-chemo-immunotherapy. Adv Funct Mater. 2019;29(19):1900004. doi:10.1002/adfm.201900004
   Web of Science ®Google Scholar
• Chen Q, Xu L, Liang C, et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016;7(1):13193. doi:10.1038/ncomms1319327767031
   PubMedGoogle Scholar
• Li Y, Li X, Doughty A, et al. Phototherapy using immunologically modified carbon nanotubes to potentiate checkpoint blockade for metastatic breast cancer. Nanomedicine. 2019;18:44–53. doi:10.1016/j.nano.2019.02.00930844573
   PubMed Web of Science ®Google Scholar
• Nam J, Son S, Ochyl LJ, Kuai R, Schwendeman A, Moon JJ. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018;9(1):1074. doi:10.1038/s41467-018-03473-929540781
   PubMedGoogle Scholar
• Jin R, Yang J, Ding P, et al. Antitumor immunity triggered by photothermal therapy and photodynamic therapy of a 2D MoS2 nanosheet-incorporated injectable polypeptide-engineered hydrogel combinated with chemotherapy for 4T1 breast tumor therapy. Nanotechnology. 2020;31(20):205102. doi:10.1088/1361-6528/ab72b932018232
   PubMed Web of Science ®Google Scholar
• Tao Y, Ju E, Liu Z, et al. Engineered, self-assembled near-infrared photothermal agents for combined tumor immunotherapy and chemo-photothermal therapy. Biomaterials. 2014;35(24):6646–6656. doi:10.1016/j.biomaterials.2014.04.07324818880
   PubMed Web of Science ®Google Scholar
• Li Y, He L, Dong H, et al. Fever-inspired immunotherapy based on photothermal CpG nanotherapeutics: the critical role of mild heat in regulating tumor microenvironment. Adv Sci. 2018;5(6):1700805. doi:10.1002/advs.201700805
   Web of Science ®Google Scholar
• Chen J, Lin L, Yan N, et al. Macrophages loaded CpG and GNR-PEI for combination of tumor photothermal therapy and immunotherapy. Sci China Mater. 2018;61(11):1484–1494. doi:10.1007/s40843-018-9238-6
   Web of Science ®Google Scholar
• Meng X, Wang K, Lv L, et al. Photothermal/photodynamic therapy with immune-adjuvant liposomal complexes for effective gastric cancer therapy. Part Part Syst Char. 2019;36(6):1900015. doi:10.1002/ppsc.201900015
   Web of Science ®Google Scholar
• Wu C, Wang L, Tian Y, et al. “Triple-punch” anticancer strategy mediated by near-infrared photosensitizer/CpG oligonucleotides dual-dressed and mitochondria-targeted nanographene. ACS Appl Mater Interfaces. 2018;10(8):6942–6955. doi:10.1021/acsami.7b1889629400948
   PubMed Web of Science ®Google Scholar
• Wu C, Guan X, Xu J, et al. Highly efficient cascading synergy of cancer photo-immunotherapy enabled by engineered graphene quantum dots/photosensitizer/CpG oligonucleotides hybrid nanotheranostics. Biomaterials. 2019;205:106–119. doi:10.1016/j.biomaterials.2019.03.02030913486
   PubMed Web of Science ®Google Scholar
• Han Q, Wang X, Jia X, et al. CpG loaded MoS2 nanosheets as multifunctional agents for photothermal enhanced cancer immunotherapy. Nanoscale. 2017;9(18):5927–5934. doi:10.1039/C7NR01460K28436514
   PubMed Web of Science ®Google Scholar
• Chen W, Qin M, Chen X, et al. Combining photothermal therapy and immunotherapy against melanoma by polydopamine-coated Al2O3 nanoparticles. Theranostics. 2018;8(8):2229–2241. doi:10.7150/thno.2407329721075
   PubMed Web of Science ®Google Scholar
• Chen R, Zhu C, Fan Y, et al. Polydopamine-based multifunctional platform for combined photothermal therapy, chemotherapy, and immunotherapy in malignant tumor treatment. ACS Appl Bio Mater. 2019;2(2):874–883. doi:10.1021/acsabm.8b00718
   PubMedGoogle Scholar
• Cano-Mejia J, Bookstaver ML, Sweeney EE, et al. Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma. Biomater Sci. 2019;7(5):1875–1887. doi:10.1039/C8BM01553H30789175
   PubMed Web of Science ®Google Scholar
• Luo L, Zhu C, Yin H, et al. Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano. 2018;12(8):7647–7662. doi:10.1021/acsnano.8b0020430020768
   PubMed Web of Science ®Google Scholar
• Yang Q, Peng J, Shi K, et al. Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy. J Control Release. 2019;308:29–43. doi:10.1016/j.jconrel.2019.06.03131252039
   PubMed Web of Science ®Google Scholar
• Peng J, Xiao Y, Li W, et al. Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy. Adv Sci. 2018;5(5):1700891. doi:10.1002/advs.201700891
   Web of Science ®Google Scholar
• Wang T, Wang D, Yu H, et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat Commun. 2018;9(1):1532. doi:10.1038/s41467-018-03915-429670088
   PubMedGoogle Scholar
• Sun W, Du Y, Liang X, et al. Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer. Biomaterials. 2019;217:119264.31260883
   PubMed Web of Science ®Google Scholar
• Ye X, Liang X, Chen Q, et al. Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy. ACS Nano. 2019;13(3):2956–2968. doi:10.1021/acsnano.8b0737130789699
   PubMed Web of Science ®Google Scholar
• Liang X, Ye X, Wang C, et al. Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Control Release. 2019;296:150–161. doi:10.1016/j.jconrel.2019.01.02730682441
   PubMed Web of Science ®Google Scholar
• Luo L, Yang J, Zhu C, et al. Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors. J Control Release. 2018;278:87–99. doi:10.1016/j.jconrel.2018.04.00229626502
   PubMed Web of Science ®Google Scholar
• Yan M, Liu Y, Zhu X, et al. Nanoscale reduced graphene oxide-mediated photothermal therapy together with IDO inhibition and PD-L1 blockade synergistically promote antitumor immunity. ACS Appl Mater Interfaces. 2018;11(2):1876–1885. doi:10.1021/acsami.8b18751
   Web of Science ®Google Scholar
• Ge R, Liu C, Zhang X, et al. Photothermal-activatable Fe3O4 superparticle nanodrug carriers with PD-L1 immune checkpoint blockade for anti-metastatic cancer immunotherapy. ACS Appl Mater Interfaces. 2018;10(24):20342–20355.29878757
   PubMed Web of Science ®Google Scholar
• Lu Q, Qi S, Li P, et al. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy. J Mater Chem B. 2019;7(15):2499–2511. doi:10.1039/C9TB00089E32255127
   PubMed Web of Science ®Google Scholar